Florbetapir F-18

First Alzheimer's blood test cleared for patients as young as 40, advancing the ADDF's long-standing push to close the gap between early pathology and early detection Milestone reflects nearly two decades of sustained ADDF investment, expanding access to scalable blood-based diagnostics to bring about a new era of clinical care NEW YORK, Aug. 20, 2026 /PRNewswire/ -- The U.S. Food and Drug Administration announced today that it has cleared C2N Diagnostics' PrecivityAD2 blood test for use in adults as young as 40 who are experiencing signs of cognitive impairment, making it the first FDA-cleared Alzheimer's blood test available to patients this young. The clearance builds on nearly 20 years of ADDF investment in C2N's science and reflects the growing momentum of blood-based diagnostics in bringing earlier, more accurate detection into mainstream care and moving the field toward a new era of precision medicine. "Today's clearance reflects how rapidly the field is advancing. Just over a year ago, there were no FDA-cleared blood tests for Alzheimer's and now we have three," said Isobel Coleman, Chief Executive Officer of the ADDF. "This is a proof point that sustained, early investment in translational science plays a catalytic role in moving promising ideas from the lab to patients. The ADDF first invested in C2N nearly two decades ago and has stayed committed as the technology matured into a diagnostic that is now transforming how Alzheimer's is detected and diagnosed. As PrecivityAD2 and tools like it move further into clinical practice, they will enable earlier detection, sharpen clinical trials, and build the foundation for precision medicine and combination therapies." The field has long recognized that Alzheimer's pathology can begin 15 to 20 years before symptoms appear. Closing that gap has been a key focus of the ADDF's work, and validated tools that reach patients earlier, including those in their 40s and 50s, help pave the way for earlier detection and, ultimately, earlier treatment. The ADDF's partnership with C2N Diagnostics began in 2008 with early seed funding that catalyzed the development of PrecivityAD, the first blood test to help diagnose Alzheimer's. This support has continued, including a $7 million investment through the ADDF's Diagnostics Accelerator (DxA), helping to establish blood-based biomarkers as a cornerstone of modern Alzheimer's research and care. Today's decision follows the FDA's clearance of Fujirebio's Lumipulse blood test, another ADDF-funded diagnostic, underscoring how early investment is driving a new generation of Alzheimer's blood tests for clinical use. The FDA's clearance of PrecivityAD2 comes at a pivotal moment, with the Alzheimer's field advancing at an unprecedented pace. PrecivityAD2 is part of the ADDF's robust diagnostics portfolio, which includes 47 active programs spanning seven different pathways. The ADDF is focused on advancing the next generation of biomarkers, including blood tests for tau and other mixed pathologies, multi-marker panels, AI-driven approaches, and diagnostics that reflect the broader pathobiology of the disease, which are key to enabling more precise treatment strategies tailored to individual patients. "PrecivityAD2 reflects how far biomarker science has come, and it points to an even bigger opportunity ahead," said Laura Nisenbaum, PhD, Interim Chief Science Officer at the ADDF. "Tests like this don't just help to diagnose Alzheimer's, they can also identify the right patients for a clinical trial and confirm whether a drug is engaging its target. That kind of precision is already reshaping trial design: 83% of active Alzheimer's trials now incorporate a biomarker. As we validate the next generation of tools, we will move closer to the same transformative approach already common in cancer care: being able to match the right drugs to the right patient at the right time." About The Alzheimer's Drug Discovery Foundation (ADDF) Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation is dedicated to rapidly accelerating the development of drugs to prevent, treat, and cure Alzheimer's disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer's, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF's leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer's PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded nearly $400 million to fund 792 Alzheimer's drug development, biomarker, and prevention programs in 21 countries. To learn more, please visit: . SOURCE Alzheimer's Drug Discovery Foundation 21% more press release views with Request a Demo

COVINGTON, Ky., Aug. 18, 2026 /PRNewswire/ -- NeuroQuant ® PET has received FDA 510(k) clearance (K261916) for PET. NeuroQuant PET ® aids physicians in the evaluation of patient pathologies and the clinical interpretation of PET performed for the assessment of cognitive impairment and other neurological conditions. Continue Reading NeuroQuant ® PET by Cortechs.ai has received FDA 510(k) clearance (K261916) for PET. As molecular imaging plays an increasingly central role in the diagnosis and management of Alzheimer's disease and related neurodegenerative disorders, the demand for standardized, objective PET analysis continues to grow. NeuroQuant® PET is designed to deliver fully automated quantification, regional analysis, and structured reporting directly into routine clinical workflows. "Automated quantitative PET imaging represents the next frontier in precision and personalized medicine for Alzheimer's disease and related neurocognitive disorders. These new technological advancements are enabling the shift from phenotype-based assessment to a biological, biomarker-driven approach in assessing neurodegenerative disease. I am excited about the role NeuroQuant PET will play in shaping the future of how these conditions are understood and managed." said Dr. Ana Franceschi, M.D., Ph.D. The platform provides atlas-based quantification for amyloid PET tracers, generating standardized uptake value ratios (SUVRs) and structured reports to support consistent, data-driven interpretation. NeuroQuant® PET segments regions of interest and quantifies Centiloids for commonly used amyloid PET tracers flutemetamol, florbetaben, and florbetapir, enabling standardized comparison across tracers and imaging systems. Compatible with PET-CT, PET-MR, and PET-only workflows, NeuroQuant® PET features fully automated processing and PACS-ready outputs designed to integrate quantitative metrics into existing workflows. "NeuroQuant® PET reflects our commitment to advancing quantitative imaging in dementia care, giving clinicians objective, reproducible measurements they can trust, so patients get earlier answers and more confident treatment decisions" said Kyle Frye, CEO of Cortechs.ai. "With FDA 510(k)-clearance status, we look forward to expanding access to standardized PET quantification that supports precision medicine in Alzheimer's disease and related dementias." About Cortechs.ai Cortechs.ai is the leader in AI applications in radiology, leveraging advanced technologies in medical imaging to enhance disease screening and timely assessment, empowering healthcare providers to deliver better outcomes for patients. The company develops and markets innovative medical imaging solution software for assessing neurological disorders such as Alzheimer's disease, epilepsy, multiple sclerosis, brain trauma, tumors and prostate cancer, helping clinicians identify and monitor clinically significant cases. Cortechs.ai's industry-leading imaging solutions offer radiologists, oncologists, and urologists streamlined, cost-effective tools to assist in the assessment of brain and prostate health, including cancer evaluation. Visit  for additional insights and follow us on Twitter, LinkedIn, and Facebook. For more information, please contact: [email protected] +1 858 459 9700 SOURCE Cortechs.ai 21% more press release views with Request a Demo